[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100615167":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":10,"locations":10,"responsibleParty":13,"collaborators":10,"id":15,"slug":10,"hasResults":16,"nctId":17,"briefTitle":18,"officialTitle":19,"acronym":20,"eligibilityCriteria":21,"healthyVolunteers":16,"sex":22,"minAge":23,"maxAge":10,"enrollmentInfo":24,"targetDuration":10,"studyType":27,"phases":10,"briefSummary":28,"conditions":29,"keywords":34,"overallStatus":41,"whyStopped":10,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":10},{"fullName":5,"class":6},"Associazione Qol-one","OTHER",[8,11],{"label":9,"type":10,"description":10,"interventionNames":10},"CAR-T",null,{"label":12,"type":10,"description":10,"interventionNames":10},"ALLO-SCT",{"type":14,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100615167",false,"NCT07289087","Patient-Reported Outcomes in Allogeneic Stem Cell Transplantation and CAR-T Therapy","A Real-World Observational Study on Patient-Reported Outcomes in Allogeneic Stem Cell Transplantation (Allo-SCT) and CAR-T Therapy","QOL-ONE PRO-CT","Inclusion Criteria:\n\n* Diagnosed with a hematologic malignancy (e.g., leukemia, lymphoma, multiple myeloma)\n* Undergoing either allogeneic SCT or CAR-T therapy\n* Able and willing to provide written informed consent\n* Sufficient Italian proficiency to complete the HM-PRO\n* Signed informed consent\n\nExclusion Criteria:\n\n* Cognitive or physical impairments that preclude the ability to complete questionnaires\n* Estimated life expectancy \\\u003C 7 days at the time of admission","ALL","18 Years",{"count":25,"type":26},162,"ESTIMATED","OBSERVATIONAL","3.1. Overview Prospective, multicenter, observational cohort study comparing short-term PROs measured with the HM-PRO between two exposure groups: patients undergoing allogeneic stem cell transplantation (allo-SCT) and patients receiving CAR-T cell therapy. Patients will be enrolled at hospital admission for the index inpatient procedure and followed through the inpatient stay (admission → discharge). The study is non-randomized and designed to describe trajectories of symptoms and HRQoL and to estimate the between-group difference in deterioration of HM-PRO scores (primary estimand: mean difference in change score, CAR-T vs allo-SCT).",[30,31,32,33],"Quality of Life","Patient Reported Outcome (PRO)","Allogeneic Blood and Marrow Transplantation (BMT)","CAR T Cell Therapy",[30,35,36,37,38,39,40],"CAR-T cell therapy","Allogenic BMT","Patient Reported Outcome","Leukemia","Multiple Myeloma","Lymphoma","NOT_YET_RECRUITING","2025-12-04",{"date":44,"type":45},"2025-12-17","ACTUAL",{"date":47,"type":26},"2026-02-15",{"date":49,"type":26},"2027-04-01",{"name":5,"class":6}]